1. ALLA AKTIER
  2. NYHETER
  3. BONESUPPORT

Bonesupport

Nyheter Bonesupport Nyheter alla bolag
Hej Visste du att du med vår premiumtjänst får fullständig historik i alla grafer, pressmeddelanden och andra notiser för dina favoritbolag direkt som DM i Discord samt en del andra godsaker? Du slipper dessutom störande annonser på sajten. Testa gratis i 14 dagar!

BONESUPPORT's Capital Markets Day

MAR

At today's Capital Markets Day BONESUPPORT AB will provide further insight into the company's operations and strategy. The focus is the US launch of BONESUPPORT's antibiotic eluting product CERAMENT G.

BONESUPPORT's group management will, among other things, announce the following:

  • CERAMENT G has been included in the contracts with Healthtrust (approx. 1,500 hospitals) and Premier (approx. 2,500 hospitals) as of October 1, 2022.
  • Launch of the "Booster program" – a focused effort to efficiently penetrate the American market with CERAMENT G.
  • Updated financial goal: 40% sales growth in the next three years (2023–2025)

The Capital Markets Day takes place today, Thursday 1 September, 14:00-16:30 at Helio, Grev Turegatan 30, in Stockholm. For physical attendance, please register here: https://financialhearings.com/event/44406

The Capital Markets Day will also be broadcast live at https://tv.streamfabriken.com/bonesupport-cmd-2022.

For more information contact:

BONESUPPORT Holding AB
Emil Billbäck, CEO
+46 (0) 46 286 53 70

Håkan Johansson, CFO
+46 (0) 46 286 53 70
ir@bonesupport.com

Cord Communications
Charlotte Stjerngren
+46 (0) 708 76 87 87
charlotte.stjerngren@cordcom.se
www.cordcom.se

This information is information that BONESUPPORT Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2022-09-01 08:00 CEST.

About BONESUPPORT™

BONESUPPORT (Nasdaq Stockholm: BONEX) develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient’s own bone and have the capability of eluting drugs. BONESUPPORT’s bone graft substitutes are based on the patented technology platform CERAMENT. The company is conducting several clinical studies to further demonstrate the clinical and health economic benefits its products deliver. The company is based in Lund, Sweden, and the net sales amounted to SEK 213 million in 2021. Please visit www.bonesupport.com for more information.
BONESUPPORT and CERAMENT are registered trademarks of BONESUPPORT AB.

Attachments

BONESUPPORT's Capital Markets Day

Datum 2022-09-01, kl 08:00
Källa MFN
Bifogade filer
BONESUPPORT's Capital Markets Day